Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?

• Axsome Therapeutics recently dosed the first patient in FOCUS-2, a Phase 3, randomized, double-blind, placebo-controlled trial evaluating solriamfetol in approximately 468 children aged 6 to under 12 with ADHD, measuring change in ADHD-RS-5 total score over 6 weeks.
• This pediatric Phase 3 start, alongside an ongoing adolescent Phase 3 program, underscores Axsome’s push to broaden solriamfetol’s role across multiple CNS indications and age groups.
• We’ll now examine how advancing solriamfetol into Phase 3 pediatric ADHD trials may influence Axsome’s CNS-focused investment narrative and risk profile.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Axsome Therapeutics Investment Narrative Recap

To own Axsome, you generally need to believe that its CNS portfolio can grow enough to offset current losses and heavy dependence on Auvelity and Sunosi. The new pediatric FOCUS-2 trial for solriamfetol supports that broader CNS story, but it does not materially change the near term focus on Auvelity execution and cash burn risk as the main catalysts and pressure points.

Among recent announcements, the start of the FOCUS-3 Phase 3 trial of solriamfetol in adolescents with ADHD is most closely tied to this news. Together with FOCUS-2, it highlights Axsome’s effort to build a multi age ADHD franchise around solriamfetol, adding to the list of late stage programs that could eventually diversify revenue, but also contribute to sustained R&D and SG&A intensity in the coming years.

Yet investors should also weigh how rising gross to net discounts across Auvelity, Sunosi and Symbravo could pressure realized revenue and margins if payer dynamics worsen...

Read the full narrative on Axsome Therapeutics (it's free!)

Axsome Therapeutics’ narrative projects $2.5 billion revenue and $981.8 million earnings by 2029.

Uncover how Axsome Therapeutics' forecasts yield a $276.47 fair value, a 21% upside to its current price.

Exploring Other Perspectives

While consensus assumes Axsome can reach about US$1.5 billion revenue and US$433.1 million earnings by 2029, the lowest analysts highlight how heavy AUVELITY dependence and broad Phase 3 spending, even after this new ADHD trial news, could still leave you with a much more cautious view on the path to profits.

Explore 7 other fair value estimates on Axsome Therapeutics - why the stock might be worth over 3x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Axsome Therapeutics research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Axsome Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Axsome Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com